Price T Rowe Associates Inc. MD Increases Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (2024)

Price T Rowe Associates Inc. MD increased its stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 15.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,952 shares of the biotechnology company’s stock after acquiring an additional 5,079 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in Aurinia Pharmaceuticals were worth $196,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 4th quarter worth about $30,000. Tidemark LLC purchased a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $39,000. Eagle Asset Management Inc. acquired a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $92,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Aurinia Pharmaceuticals by 67.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 27,802 shares of the biotechnology company’s stock worth $139,000 after buying an additional 11,189 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $158,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Performance

NASDAQ:AUPH opened at $6.26 on Friday. The company’s 50-day moving average price is $5.57 and its 200-day moving average price is $5.59. The company has a current ratio of 5.60, a quick ratio of 5.05 and a debt-to-equity ratio of 0.19. The company has a market cap of $893.08 million, a P/E ratio of -14.56 and a beta of 1.44. Aurinia Pharmaceuticals Inc. has a twelve month low of $4.71 and a twelve month high of $10.24.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last issued its earnings results on Thursday, August 1st. The biotechnology company reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. Aurinia Pharmaceuticals had a negative net margin of 24.31% and a negative return on equity of 11.75%. The company had revenue of $57.10 million for the quarter, compared to the consensus estimate of $54.25 million. During the same period in the previous year, the firm earned ($0.08) earnings per share. Aurinia Pharmaceuticals’s quarterly revenue was up 37.6% compared to the same quarter last year. On average, sell-side analysts forecast that Aurinia Pharmaceuticals Inc. will post 0.15 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aurinia Pharmaceuticals news, insider Scott Michael Habig sold 18,249 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $5.31, for a total transaction of $96,902.19. Following the transaction, the insider now directly owns 456,338 shares of the company’s stock, valued at $2,423,154.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, StockNews.com raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $10.00.

Check Out Our Latest Research Report on AUPH

Aurinia Pharmaceuticals Company Profile

(Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Featured Stories

• Five stocks we like better than Aurinia Pharmaceuticals
• How Investors Can Identify and Successfully Trade Gap-Down Stocks
• Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
• Low PE Growth Stocks: Unlocking Investment Opportunities
• MarketBeat Week in Review – 8/12 – 8/16
• 3 Ways To Invest In Coffee, Other Than Drinking It
• JD.com Earnings Surprise: China’s Outlook Better Than Expected

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.